Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.
Déborah HirtM OualhaB PasquiersS BlanotR RubinstazjnC GlorionS El MessaoudiD DrummondV LopezJ ToubianaA BérangerSana BoujaafarYi ZhengCarmen CapitoS WinterP L LégerR BerthaudInès GanaF FoissacJ M TréluyerN BouazzaS BenaboudPublished in: European journal of clinical pharmacology (2021)
The recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella). A dose increase to 600 mg q8h in children > 40 kg and to 15 mg/kg q8h (max 400 mg q8h, max 600 mg q8h if augmented renal clearance, i.e., eGFR > 200 mL/min/1.73 m2) in children < 40 kg would be needed for the strains with highest MIC (16% of Pseudomonas aeruginosa and 47% of Staphylococcus aureus). The oral recommended dose of 20 mg/kg q12h (not exceeding 750 mg) would cover bacteria with MICs ≤ 0.125 but may be insufficient for bacteria with higher MIC and a dose increase according bodyweight and eGFR would be needed. These doses should be prospectively confirmed, and a therapeutic drug monitoring could be used to refine them individually.